Financial News
Latest News about ROIV
Recent news which mentions ROIV
'I'm One Of You' – How 'Anti-Woke' Warrior Vivek Ramaswamy Became A Billionaire At Only 38
November 18, 2024
From Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
From Benzinga
Price Over Earnings Overview: Roivant Sciences
October 18, 2024
From Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
October 03, 2024
From Benzinga
Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
October 03, 2024
From Benzinga
From Benzinga
4 Analysts Assess Roivant Sciences: What You Need To Know
September 11, 2024
Tickers
ROIV
From Benzinga
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
September 10, 2024
From Benzinga
From Benzinga
Tickers
ROIV
From InvestorPlace
From Benzinga
From InvestorPlace
From InvestorPlace
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
March 29, 2024
From Benzinga
5 Value Stocks In The Healthcare Sector
February 19, 2024
From Benzinga
Earnings Scheduled For February 13, 2024
February 13, 2024
From Benzinga
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
January 10, 2024
From Benzinga
Assessing Roivant Sciences: Insights From 5 Financial Analysts
January 02, 2024
Tickers
ROIV
From Benzinga
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
December 21, 2023
From Benzinga
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
December 20, 2023
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
